Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency
2019-09-23 18:00
CPhI recruiting freelance pharmaceutical authors contributing to the global industry professionals
2019-09-23 17:56
New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care
2019-09-23 14:00
2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors
2019-09-22 14:22
2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab
2019-09-22 13:39
2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors
2019-09-21 00:26
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
2019-09-20 20:34
Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO
2019-09-20 14:30
2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%
2019-09-19 23:48
Advanced Aesthetic Technologies and China National Biotec Group Announce Strategic Cooperation
2019-09-19 23:12
Chipscreen Biosciences's Oringinal New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted
2019-09-19 23:02
Tresiba® Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes
2019-09-19 18:01
Innovent Provides Update on the Results of IBI305 for the First-line Treatment of Advanced Non-squamous Cell Lung Cancer by Oral Presentation at CSCO
2019-09-19 16:36
China Biologic Announces Receipt of Preliminary Non-Binding "Going Private" Proposal
2019-09-19 04:01
Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection
2019-09-17 21:00
AMPAC Fine Chemicals and SK biotek Become New US Corporation Focused on Expanded Support to the World's Pharmaceutical Industry
2019-09-17 04:35
Ping An Good Doctor Joins Forces with the People's Government of Guangxi Zhuang Autonomous Region to Build Internet Healthcare Platform Opening up a Window for ASEAN to Seek Healthcare Services
2019-09-16 21:04
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins Using Mass Spectrometry
2019-09-16 16:01
Patient Priorities Should be Paramount when Measuring Quality in Cancer Care According to Panelists at NCCN Policy Summit
2019-09-13 01:30
Traditional Chinese Medicine Giant DEEJ Partners with 111 for Direct Sourcing
2019-09-12 23:16
1
318
319
320
321
322
412